The efficacy and safety of omadacycline plus β-lactam versus moxifloxacin plus β-lactam for the treatment of severe community-acquired pneumonia: study protocol of a multicenter, prospective, randomized controlled non-inferiority trial
Infection · 2026-10 · 54 (5) · 2653-2662
DOI: 10.1007/s15010-026-02897-6 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Infection, online erschienen am 11.08.2026. Verfasst von Xin Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Senior Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital, Bei…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta Lactam Antibiotics, Community-Acquired Pneumonia, Moxifloxacin. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Logistics support Ministry special subject.
Abstract (Originalsprache)
BACKGROUND: Severe community-acquired pneumonia (sCAP) is associated with high morbidity and mortality. Current empirical antimicrobial regimens are increasingly challenged by rising antimicrobial resistance and safety concerns (e.g., fluoroquinolone-related adverse events). Omadacycline, a novel aminomethylcycline antibiotic, has demonstrated broad-spectrum activity against common respiratory pathogens (including drug-resistant strains) and a favorable safety profile. However, direct comparative evidence to support its use in combination with β-lactams in this setting is lacking. Therefore, the primary objective of this trial is to evaluate whether omadacycline combined with a β-lactam is non-inferior to the standard β-lactam plus moxifloxacin regimen for the treatment of sCAP in adults. METHODS: This is a multicenter, prospective, randomized, open-label, active-controlled, non-inferiority trial conducted across 8 tertiary hospitals in China. Eligible participants are adult patients (≥ 18 years old) who meet the IDSA/ATS 2019 diagnostic criteria for sCAP, with no contraindications to the study drugs (omadacycline, β-lactams, or moxifloxacin) and able to complete follow-up. A total of 248 patients will be recruited and randomized in a 1:1 allocation ratio to either of the two arms. The experimental arm will receive omadacycline (200 mg iv once daily for the first day, then 100 mg iv q24h) plus β-lactam therapy (piperacillin-tazobactam 4.5 g iv q8h or meropenem 1 g iv q8h). The control arm will receive moxifloxacin (400 mg iv q24h) plus the same β-lactam regimen. The treatment duration for both groups will be 7-14 days, adjusted based on clinical response. The primary endpoint is early clinical response at 72-96 h (defined as improvement in ≥ 2 major clinical symptoms/signs of pneumonia without worsening of any other major symptom/sign). Secondary endpoints include clinical cure at the end of treatment, 28-day all-cause mortality, epidemiology of pathogens of severe CAP, time to clinical stability, incidence of adverse events, and length of hospital stay. This trial has obtained ethical approval from the Ethics Committee of the leading center (Approval Number: [KY-2025-8-167-1]). The study protocol has been filed with the Ethics Committees of all other participating hospitals in accordance with relevant regulatory requirements, and all patients will provide written informed consent prior to enrollment. DISCUSSION: This trial aims to evaluate the non-inferiority of the omadacycline-plus-β-lactam regimen versus the standard fluoroquinolone-based combination in patients with severe CAP. If non-inferiority is demonstrated, this novel regimen could offer a safer alternative that reduces fluoroquinolone-associated adverse events, preserves the utility of existing antibiotic classes, and may provide a potential option for addressing multidrug-resistant pathogens. These findings would directly inform empirical antibiotic selection and antimicrobial stewardship strategies across both general wards and intensive care units. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2500109407. Registered on 17 September 2025. (https//www.chictr.org.cn/showproj.html? proj=286992).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Senior Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital, Beijing, China.
- Senior Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China.
- Department of Respiratory and Critical Care Medicine, Senior Department of Respiratory and Critical Care Medicine, The First Medical Center of PLA General Hospital, Beijing, China.
- Senior Department of Respiratory and Critical Care Medicine, The Eighth Medical Center of PLA General Hospital, Beijing, China. xielx301@126.com.
- Senior Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China. fswang302@163.com.
- Department of Respiratory and Critical Care Medicine, Senior Department of Infectious Diseases, The Fifth Medical Center of PLA General Hospital, Beijing, China. xinyuannatile@sina.com.
Förderung
- Logistics support Ministry special subject
Zitieren
APA
Zhang, X., She, D., Shi, Y., Bai, Y., Fang, Y., Niu, W., Xin, R., Yang, N., Xie, L., Wang, F., & Yuan, X. (2026). The efficacy and safety of omadacycline plus β-lactam versus moxifloxacin plus β-lactam for the treatment of severe community-acquired pneumonia: study protocol of a multicenter, prospective, randomized controlled non-inferiority trial. Infection, 54(5), 2653-2662. https://doi.org/10.1007/s15010-026-02897-6
Vancouver
Zhang X, She D, Shi Y, Bai Y, Fang Y, Niu W, et al. The efficacy and safety of omadacycline plus β-lactam versus moxifloxacin plus β-lactam for the treatment of severe community-acquired pneumonia: study protocol of a multicenter, prospective, randomized controlled non-inferiority trial. Infection. 2026;54(5):2653-2662. doi:10.1007/s15010-026-02897-6
BibTeX
@article{Zhang2026,
author = {Zhang, Xin and She, Danyang and Shi, Yinghui and Bai, Yunbiao and Fang, Yun and Niu, Wenkai and Xin, Ruixia and Yang, Ning and Xie, Lixin and Wang, Fusheng and Yuan, Xin},
title = {The efficacy and safety of omadacycline plus β-lactam versus moxifloxacin plus β-lactam for the treatment of severe community-acquired pneumonia: study protocol of a multicenter, prospective, randomized controlled non-inferiority trial},
journal = {Infection},
year = {2026},
volume = {54},
number = {5},
pages = {2653--2662},
doi = {10.1007/s15010-026-02897-6}
}
EUVIMED